JP2022518210A - インテグリンαvβ3に特異的な二環式ペプチドリガンド - Google Patents

インテグリンαvβ3に特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022518210A
JP2022518210A JP2021540822A JP2021540822A JP2022518210A JP 2022518210 A JP2022518210 A JP 2022518210A JP 2021540822 A JP2021540822 A JP 2021540822A JP 2021540822 A JP2021540822 A JP 2021540822A JP 2022518210 A JP2022518210 A JP 2022518210A
Authority
JP
Japan
Prior art keywords
seq
referred
sar
peptide ligand
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518210A5 (https=
JPWO2020148527A5 (https=
Inventor
ラニ ラシッド
ステイス キャサリン
トイフェル ダニエル
ウォーカー エドワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2022518210A publication Critical patent/JP2022518210A/ja
Publication of JP2022518210A5 publication Critical patent/JP2022518210A5/ja
Publication of JPWO2020148527A5 publication Critical patent/JPWO2020148527A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/70557Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021540822A 2019-01-15 2020-01-15 インテグリンαvβ3に特異的な二環式ペプチドリガンド Pending JP2022518210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1900527.1 2019-01-15
GBGB1900527.1A GB201900527D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for integrin avb3
PCT/GB2020/050071 WO2020148527A1 (en) 2019-01-15 2020-01-15 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3

Publications (3)

Publication Number Publication Date
JP2022518210A true JP2022518210A (ja) 2022-03-14
JP2022518210A5 JP2022518210A5 (https=) 2023-01-25
JPWO2020148527A5 JPWO2020148527A5 (https=) 2023-01-25

Family

ID=65528151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540822A Pending JP2022518210A (ja) 2019-01-15 2020-01-15 インテグリンαvβ3に特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220064221A1 (https=)
EP (1) EP3966233A1 (https=)
JP (1) JP2022518210A (https=)
CN (1) CN113439088A (https=)
GB (1) GB201900527D0 (https=)
WO (1) WO2020148527A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Pd-l1に特異的な二環式ペプチドリガンド
GB201900528D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009211253B2 (en) 2008-02-05 2014-11-06 Bicyclerd Limited Methods and compositions
WO2011079015A1 (en) * 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Also Published As

Publication number Publication date
GB201900527D0 (en) 2019-03-06
US20220064221A1 (en) 2022-03-03
CN113439088A (zh) 2021-09-24
EP3966233A1 (en) 2022-03-16
WO2020148527A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP2022518210A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022518695A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022514618A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022517442A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022514255A (ja) Psmaに特異的な二環式ペプチドリガンド
JP2022514687A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022512478A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022517040A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2022513223A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022513806A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2021506936A (ja) EphA2に特異的な二環ペプチドリガンド
CA3154672A1 (en) Bicyclic peptide ligand drug conjugates
JP2022517399A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ox40に特異的な二環式ペプチドリガンド
JP2020529427A (ja) Cd137に対して特異的な二環式ペプチドリガンド
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
JP2022515720A (ja) Il-17に特異的な二環式ペプチドリガンド
JP2022515721A (ja) FAPαに特異的な二環式ペプチドリガンド
EA046810B1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723